Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shaji Kumar

Showing results (231-240 of 516) with videos related to

Pageof 52
Sort By:
The Oncologist|April 24, 2022
Daratumumab Improves Depth of Response and Progression-free Survival in Transplant-ineligible, High-risk, Newly Diagnosed Multiple MyelomaAndrzej J Jakubowiak, Shaji Kumar, Rohan Medhekar, et al.
Blood Cancer Journal|February 10, 2021
Mass spectrometry for the evaluation of monoclonal proteins in multiple myeloma and related disorders: an International Myeloma Working Group Mass Spectrometry Committee ReportDavid L Murray, Noemi Puig, Sigurdur Kristinsson, et al.
Blood Cancer Journal|July 26, 2022
Distribution of clonal hematopoiesis of indeterminate potential (CHIP) is not associated with race in patients with plasma cell neoplasmsMarie-France Gagnon, Shulan Tian, Susan Geyer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 3, 2007
Neutralizing B-cell activating factor antibody improves survival and inhibits osteoclastogenesis in a severe combined immunodeficient human multiple myeloma modelPaola Neri, Shaji Kumar, Maria Teresa Fulciniti, et al.
Genes, Chromosomes & Cancer|June 14, 2021
Increased complexity of t(11;14) rearrangements in plasma cell neoplasms compared with mantle cell lymphomaJoanna C Dalland, James B Smadbeck, Neeraj Sharma, et al.
Medical Physics|August 19, 2022
Deep learning-based virtual noncalcium imaging in multiple myeloma using dual-energy CTHao Gong, Francis I Baffour, Katrina N Glazebrook, et al.
European Journal of Haematology|June 8, 2012
Evaluation of pretransplant factors predicting cardiac dysfunction following high-dose melphalan conditioning and autologous peripheral blood stem cell transplantationJonathan S Bleeker, Morie A Gertz, Patricia A Pellikka, et al.
British Journal of Haematology|October 12, 2013
Akt inhibitor MK2206 selectively targets CLL B-cell receptor induced cytokines, mobilizes lymphocytes and synergizes with bendamustine to induce CLL apoptosisWei Ding, Tait D Shanafelt, Connie E Lesnick, et al.
Mayo Clinic Proceedings|June 9, 2012
Use of nonclonal serum immunoglobulin free light chains to predict overall survival in the general populationAngela Dispenzieri, Jerry A Katzmann, Robert A Kyle, et al.
Blood|August 21, 2004
Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myelomaNoopur Raje, Shaji Kumar, Teru Hideshima, et al.
Pageof 52

Showing results (231-240 of 516) with videos related to

Sort By:
Pageof 52
The Oncologist|April 24, 2022
Daratumumab Improves Depth of Response and Progression-free Survival in Transplant-ineligible, High-risk, Newly Diagnosed Multiple MyelomaAndrzej J Jakubowiak, Shaji Kumar, Rohan Medhekar, et al.
Blood Cancer Journal|February 10, 2021
Mass spectrometry for the evaluation of monoclonal proteins in multiple myeloma and related disorders: an International Myeloma Working Group Mass Spectrometry Committee ReportDavid L Murray, Noemi Puig, Sigurdur Kristinsson, et al.
Blood Cancer Journal|July 26, 2022
Distribution of clonal hematopoiesis of indeterminate potential (CHIP) is not associated with race in patients with plasma cell neoplasmsMarie-France Gagnon, Shulan Tian, Susan Geyer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 3, 2007
Neutralizing B-cell activating factor antibody improves survival and inhibits osteoclastogenesis in a severe combined immunodeficient human multiple myeloma modelPaola Neri, Shaji Kumar, Maria Teresa Fulciniti, et al.
Genes, Chromosomes & Cancer|June 14, 2021
Increased complexity of t(11;14) rearrangements in plasma cell neoplasms compared with mantle cell lymphomaJoanna C Dalland, James B Smadbeck, Neeraj Sharma, et al.
Medical Physics|August 19, 2022
Deep learning-based virtual noncalcium imaging in multiple myeloma using dual-energy CTHao Gong, Francis I Baffour, Katrina N Glazebrook, et al.
European Journal of Haematology|June 8, 2012
Evaluation of pretransplant factors predicting cardiac dysfunction following high-dose melphalan conditioning and autologous peripheral blood stem cell transplantationJonathan S Bleeker, Morie A Gertz, Patricia A Pellikka, et al.
British Journal of Haematology|October 12, 2013
Akt inhibitor MK2206 selectively targets CLL B-cell receptor induced cytokines, mobilizes lymphocytes and synergizes with bendamustine to induce CLL apoptosisWei Ding, Tait D Shanafelt, Connie E Lesnick, et al.
Mayo Clinic Proceedings|June 9, 2012
Use of nonclonal serum immunoglobulin free light chains to predict overall survival in the general populationAngela Dispenzieri, Jerry A Katzmann, Robert A Kyle, et al.
Blood|August 21, 2004
Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myelomaNoopur Raje, Shaji Kumar, Teru Hideshima, et al.
Pageof 52